Table 1. Comparison of baseline demographics.
| Total (n=34) | Limited SSc (n=6) | Diffuse SSc (n=28) | P | ||||||||||
| n | % | Median | Min-Max | n | % | Median | Min-Max | n | % | Median | Min-Max | ||
| Demographic characteristics | |||||||||||||
| Age (year) | 50.0 | 25.0-72.0 | 57.0 | 51.0-66.0 | 48.00 | 25.0-72.0 | 0.0375 | ||||||
| Sex | 6 | 100.0 | 26 | 92.86 | 1.0000 | ||||||||
| Female | 32 | 94.12 | |||||||||||
| Weight (kg) | 54.35 | 42.10-81.0 | 57.50 | 48.20-65.80 | 53.45 | 42.10-81.00 | 0.5111 | ||||||
| Body mass index (kg/m2) | 21.8 | 16.70-34.60 | 23.35 | 21.40-25.10 | 21.65 | 16.70-34.60 | 0.200 | ||||||
| Disease duration (month) | 16.5 | 2.00-144.00 | 6.00 | 3.00-26.00 | 21.50 | 2.00-144.00 | 0.0237 | ||||||
| Raynaud’s phenomenon | |||||||||||||
| Yes | 30 | 88.24 | 5 | 83.33 | 25 | 89.29 | 0.5585 | ||||||
| RP duration (month) | 25.0 | 3.0-144.0 | 6.00 | 3.0-26.0 | 32.00 | 5.0-144.0 | 0.0257 | ||||||
| Autoantibodies | |||||||||||||
| Antinuclear antibody | 34 | 100.0 | 6 | 100.0 | 28 | 100.0 | NA | ||||||
| Anti-centromere Ab | 9 | 26.47 | 5 | 83.33 | 4 | 14.29 | 0.0024 | ||||||
| Anti-scl70 Ab | 17 | 50.0 | 0 | 0.0 | 17 | 60.71 | 0.0184 | ||||||
| Organ involvement | |||||||||||||
| Interstitial lung disease | 26 | 76.47 | 3 | 50.00 | 23 | 82.14 | |||||||
| GI involvement | 13 | 38.24 | 2 | 33.33 | 11 | 39.29 | |||||||
| Scleroderma renal crisis | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Pulmonary arterial hypertension | 5 | 14.71 | 0 | 0.00 | 5 | 17.86 | |||||||
| Arthralgia | 8 | 23.53 | 2 | 33.33 | 6 | 21.43 | |||||||
| Modified Rodnan skin score | 17.5 | 2-40 | 12.50 | 6-28 | 18.00 | 2-40 | |||||||
| Previous DU | 6 | 17.65 | |||||||||||
| DU within 1 month | 4 | 11.76 | 0 | 0.0 | 6 | 21.43 | |||||||
| Largest diameter (mm) | 5.50 | 2.0-10.0 | 0 | 0.0 | 4 | 14.29 | |||||||
| Nailfold capillaroscopy | 5.50 | 2.00-10.00 | |||||||||||
| Megacapillary grade (0-3) | 1 | 0-2 | 1.00 | 0-2 | 1.00 | 0-2 | 0.8843 | ||||||
| Avascular area grade (0-3) | 2 | 0-3 | 2.00 | 2-3 | 2.00 | 0-2 | 0.0744 | ||||||
| Ramification grade (0-3) | 0 | 0-2 | 0.00 | 0-0 | 0.00 | 0-2 | 0.5326 | ||||||
| HRCT | |||||||||||||
| Normal-minimal | 5 | 15.5 | 1 | 16.67 | 4 | 14.81 | 0.0576 | ||||||
| UIP | 5 | 15.5 | 3 | 50.00 | 2 | 7.41 | |||||||
| NSIP | 22 | 66.67 | 2 | 33.33 | 20 | 74.07 | |||||||
| LIP | 1 | 3.03 | 0 | 0.00 | 1 | 3.70 | |||||||
| Pulmonary function test | |||||||||||||
| FVC % predicted | 75.0 | 42.0-116.0 | 110.50 | 109.0-116.0 | 68.50 | 42.00-112.00 | 0.0035 | ||||||
| FEVi % predicted | 84.0 | 46.0-120.0 | 114.50 | 112.00-20.00 | 79.50 | 46.00-112.00 | 0.0022 | ||||||
| DLCO % predicted Previous medication |
62.5 | 33.0-87.0 | 78.50 | 62.00-87.00 | 61.50 | 33.00-87.00 | 0.0566 | ||||||
| Prednisolone | 30 | 88.24 | 5 | 83.33 | 25 | 89.29 | 0.5585 | ||||||
| Mean dose (previous 1 month) (mg/day) | 5.0 | 0.0-15.0 | 5.00 | 0.00-15.00 | 5.00 | 0.00-15.00 | 1.0000 | ||||||
| CCB | 16 | 47.06 | 5 | 83.33 | 11 | 39.29 | 0.0782 | ||||||
| ARB/ACEi | 11 | 32.35 | 1 | 16.67 | 10 | 35.71 | 0.6379 | ||||||
| Aspirin | 6 | 17.65 | 1 | 16.67 | 5 | 17.86 | 1.0000 | ||||||
| CYC | 19 | 55.88 | 2 | 33.33 | 17 | 60.71 | 0.3696 | ||||||
| Total dose of CYC, mg | 525.0 | 1000-12000 | 4625.0 | 4000-5250 | 5750.0 | 1000-12000 | 0.2501 | ||||||
| Methotrexate | 8 | 23.53 | 1 | 16.67 | 7 | 25.0 | 1.0000 | ||||||
| Mean dose (previous 1 month) (mg/week) | 10 | 10.0-10.0 | 10.00 | 10.0-10.0 | 10.00 | 10.0-10.0 | 1.0000 | ||||||
| SSc: Systemic sclerosis; Min: Minimum; Max: Maximum; RP: Raynaud’s phenomenon; Ab: Antinuclear antibody; Anti-scl70: Anti-topoisomerase I; GI: Gastrointestinal; DU: Digital ulcer; HRCT: High-resolution computed tomography; UIP: Usual interstitial pneumonia; NSIP: Non-specific interstitial pneumonia; LIP: Lymphocytic interstitial pneumonia; FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second; DLCO: Diffusing capacity of lung for carbon monoxide; CCB: Calcium channel blocker; ARB: angiotension II receptor blocker; ACEi: angiotensin converting enzyme inhibitors; CYC: cyclophosphamide. | |||||||||||||